...ジン脱炭酸酵素]]の補因子である。これにより、[[histidine/ja|ヒスチジン]]からヒスタミンへの変換が可能になる。この反応は[[mast cell/ja|肥満細胞]]や[[basophil/ja|好塩基球]]の[[Golgi apparatus/ja|ゴルジ装置]]で起こる。次に、ヒスタミンは、肥
...
19 KB (667 words) - 15:02, 4 April 2024
...cell]]s and in [[basophil]]s. Next, histamine is stored in granularity in mast cells as a complex with acid residues of [[heparin]] proteoglycan while in
...r of the BRISC deubiquitylase enzyme complex, which regulates immune-based cell signaling. Recent studies show that SJMT2 tetramerization is induced by PLP
...
16 KB (2,151 words) - 21:34, 3 April 2024
...cell]]s and in [[basophil]]s. Next, histamine is stored in granularity in mast cells as a complex with acid residues of [[heparin]] proteoglycan while in
...r of the BRISC deubiquitylase enzyme complex, which regulates immune-based cell signaling. Recent studies show that SJMT2 tetramerization is induced by PLP
...
16 KB (2,219 words) - 21:34, 3 April 2024
...子治療]]、[[Monoclonal antibody/ja|モノクローナル抗体]]、[[cell therapy/ja|細胞治療]]（[[stem cell/ja|幹細胞]]治療など）を含むバイオ医薬品の区別である。その他、作用機序、[[route of administration|投与経路]]、影響を受
...a|IVIG]]など）、[[gene therappy/ja|遺伝子治療]]、[[cell therapy/ja|細胞治療]]（例えば、[[stem cell/ja|幹細胞]]治療）を含む）との間の分類である。
...
58 KB (1,845 words) - 17:09, 5 November 2023
...bodies]] and [[cell therapy|cell therapy]] (for instance, [[stem cell|stem cell]] therapies). Other ways to classify medicines are by mode of action, [[rou
...erapy]], and [[cell therapy|cell therapy]] (for instance, [[stem cell|stem cell]] therapies).
...
52 KB (6,923 words) - 17:09, 5 November 2023
...bodies]] and [[cell therapy|cell therapy]] (for instance, [[stem cell|stem cell]] therapies). Other ways to classify medicines are by mode of action, [[rou
...erapy]], and [[cell therapy|cell therapy]] (for instance, [[stem cell|stem cell]] therapies).
...
54 KB (7,245 words) - 17:08, 5 November 2023